Table 3 Univariate analysis of overall survival

Variable	N	Events	Median survival (months)	95% Confidence interval (months)	P- value ^a
Overall	177	102	83.3	58.9–107.7
HIF-1α
Negative	95	56	79.6	45.5–113.7
Positive	60	38	77.6	40.8–114.4	0.91
HIF-2α
Negative	74	37	101.5	81.5–120.7
Positive	85	55	57.4	36.1–78.7	0.027
CA9
Negative	55	32	79.6	30.2–128.9
Positive	110	66	79.1	48.1–110.1	0.87
VEGF
Negative	20	10	83.3	72.6–94.0
Positive	149	88	79.6	49.2–110.0	0.46
Dll4 Endo.
Negative	50	29	64.0	9.0–118.0
Positive	125	72	89.0	64.2–113.6	0.94
PHD1
Negative	46	26	79.1	46.0–112.2
Positive	116	69	88.9	56.2–121.6	0.71
PHD2
Negative	29	13	111.5	NR
Positive	135	83	66.7	37.7–95.7	0.08
PHD3
Negative	52	29	97.8	68.2–127.4
Positive	120	70	68.9	39.9–97.8	0.67
pT stage
1	5	2	NR
2	13	4	NR
3	77	37	110.9	97.9–124.0
4	82	59	45.0	32.4–57.6	0.0003
pN stage
0	103	45	139.9	98.1–181.7
1	43	31	49.2	25.6–72.7
2	28	24	18.1	1.8–34.3
3	3	2	21.1	0–43.8	<0.0001
M stage
0	156	82	100.0	82.1–118.0
1	21	20	9.2	5.1–13.3	<0.0001
LI
Absent	150	84	91.9	71.2–112.6
Present	22	16	18.0	3.6–32.5	0.007
VI
Absent	131	70	97.6	73.6–121.7
Present	41	30	23.1	0–52.4	0.002
Grade
Good	46	22	111.0	94.9–127.1
Moderate	101	64	64.0	34.1–93.9
Poor	11	8	28.9	0–83.5	0.028
Sex
Female	80	45	88.9	61.6–116.2
Male	97	57	79.6	40.3–118.8	0.68
Site
Distal	73	45	77.6	41.7–113.5
Proximal	104	57	88.9	57.7–120.0	0.50
AC
No	110	56	101.1	82.5–119.7
Yes	67	46	54.4	41.0–67.8	0.003

Abbreviations: AC=adjuvant chemotherapy; Endo.=endothelial; LI=lymphatic invasion; NR=not reached; VI=vascular invasion; PHD=prolyl hydroxylase; VEGF=vascular endothelial growth factor; CA9=carbonic anhydrase 9; HIF=hypoxia-inducible factor; Dll4=delta-like ligand 4.
^aLog-rank test (Mantel–Cox).

Quick links

Search